Name | Country | Strength | Pack Size | USD | Cart | ||||
---|---|---|---|---|---|---|---|---|---|
![]() |
Sinemet CR | levodopa/carbidopa er | Brand | United Kingdom | 100mg/10mg | 100 Tablets | DR | $35.54 | Add |
![]() |
Sinemet CR | levodopa/carbidopa er | Brand | United Kingdom | 200mg/50mg | 60 Tablets | DR | $46.08 | Add |
![]() |
Sinemet CR | levodopa/carbidopa er | Brand | United Kingdom | 100mg/25mg | 60 Tablets | DR | $46.08 | Add |
![]() |
Sinemet CR | levodopa/carbidopa er | Brand | United Kingdom | 250mg/25mg | 100 Tablets | DR | $71.09 | Add |
![]() |
Sinemet CR/Syndopa CR | levodopa/carbidopa er | Brand | India | 200mg/50mg | 100 Tablets | DR | $29.99 | Add |
![]() |
Half Sinemet CR | carbidopa/levodopa | Brand | United Kingdom | 25 mg/100 mg Prolonged-Release Tablets | 60 | DR | $49.55 | Add |
![]() |
Sinemet CR | levodopa/carbidopa er | Brand | New Zealand | 200mg/50mg | 100 TAB | RX | $117.00 | Add |
Medicines have benefits and some have risks. Always read the label and use only as directed. If symptoms persist or you have side effects see your health professional. Brands and generics both contain the same active ingredient(s) and are medically equivalent. Some brands are marketed under different names by the same manufacturer depending on the country of origin. Images are provided as a reference only, the received medicine may vary in packaging, color, pill shape, etc, from one batch to the next. For an item marked "generic" any quality brand may be sent, however you will always receive the active ingredients ordered in the strength(s) ordered.
Sinemet CR (levodopa, carbidopa) is a combination antiparkinsonian medication, predominantly used to help resolve movement disorders associated with Parkinson's disease or Parkinson's syndrome. It may also be used off-label to help with other conditions, such as restless leg syndrome.
The CR in this product's name indicates it is controlled release, compared to the fast-acting version of regular Sinemet. Some patients find the CR version works better, though others find the fast-acting version is more effective. Note that CR tablets cannot be crushed, chewed, or otherwise damaged; doing so will destroy their CR properties and may result in too much medication at once.
Sinemet and Sinemet CR are the first-line, gold standard treatment for Parkinson's.
How it Works
Like many Parkinson's medications, Sinemet CR works by increasing the level of dopamine in the brain. It contains two active ingredients, which work together to provide benefit:
Sinemet CR definitely provides significant benefit in the majority of patients who take it; it alleviates symptoms of slow movements, stiff muscles, tremors, and so forth. However, it is not a cure and it will not slow progression of the disease.
There will come a time when Sinemet CR's benefit begins to wane; the medication will be less effective, on-off syndrome may become more pronounced, resistance to the medication may develop, and there is some evidence that long-term use contributes to dopamine dysregulation. Long-term use is also associated with increased risk of dyskinesia, spontaneous, involuntary movements.
At some point, when the medication no longer provides benefit or negative side effects outweigh its benefit, treatment may end.
Benefits of the CR Version
The biggest benefit of Sinemet CR versus the fast-acting version has to do with keeping levels of the drug consistent in the body, which can provide greater benefit both in helping with muscle stiffness and preventing side effects.
On-off syndrome describes the fluctuation between feeling good and feeling bad; as levels of the drug increase and peak in the body the patient feels good, as they wane away the patients feels bad. This happens relatively rapidly with fast-acting versions; it is considerably slower with Sinemet CR.
At peak levels dyskinesia symptoms may also develop. Patients taking Sinemet CR are often able to avoid these symptoms when they are experienced with regular Sinemet, as more regular levels of the drug reduce both highs and lows.
There are always exceptions; Sinemet CR may not alleviate these effects in all patients, particularly at higher doses or if the disease has progressed for some time.
Dosage & Administration
Sinemet CR is available in tablets for most patients. Those unable to swallow whole tablets may be able to get this medication in a gel or as orally-dissolving tablets.
Treatment is highly individualized, and thus highly variable. Patients are strongly advised to consult a doctor about dosage, frequency of administration, and discontinuing treatment.
Dosage is typically limited by amount of levodopa, rather than carbidopa. Most patients take somewhere between 400 to 1600 mg of levodopa per day, which is divided into smaller doses that may be taken as frequently as every 4 hours throughout the day.
Treatment usually begins with low doses, increased if needed. Dosage should not be increased more frequently than every three days. It's not unusual for dosage to gradually increase over time as the disease progresses.
Sinemet CR should not be discontinued abruptly; speak with a doctor about a discontinuation plan.
There are numerous other medications that can help with Parkinson's; sometimes one or more will be given along with Sinemet CR. This may affect dosage of one or more of the medications involved; do not start taking additional medications without first clearing them with a doctor.
Precautions
Sinemet CR can cause drowsiness; some patients fall asleep with little warning. Use caution performing dangerous tasks---such as driving or operating machinery---until effects of Sinemet CR are known.
Sinemet CR can cause urine, saliva, or sweat to become discolored, even dark red or black. While this may appear alarming it is not cause for concern.
Other medications can interact with Sinemet; be sure the prescribing doctor is aware if taking:
Other conditions that may influence dosage include:
Speak with a doctor before taking Sinemet or Sinemet CR if trying to get pregnant, pregnant, or breastfeeding.
Nobody has left a review yet for SINEMET CR, why not be the first?